CanSino Biologics (06185.HK) announces its performance in the first half of the year, with a net loss attributable to shareholders of 13.485 million yuan, a year-on-year decrease of 94.02%.

The intelligent finance and economics app announced that Kangxinuo Biology (06185.HK) released its performance for the first half of 2025, with revenue of approximately 374 million yuan, a year-on-year increase of 31.1%. Research and development expenses decreased by 20.5% year-on-year to approximately 148 million yuan, and the owner's share of the company's loss in the period was 13.485 million yuan, a year-on-year decrease of 94.02%. Loss per share was 0.05 yuan.